GH
Guardant Health, Inc. NASDAQ Listed Oct 4, 2018$92.40
Mkt Cap $12.1B
52w Low $36.36
66.4% of range
52w High $120.74
50d MA $88.78
200d MA $84.24
P/E (TTM)
-26.4x
EV/EBITDA
-37.7x
P/B
—
Debt/Equity
-16.9x
ROE
419.2%
P/FCF
-54.9x
RSI (14)
—
ATR (14)
—
Beta
1.65
50d MA
$88.78
200d MA
$84.24
Avg Volume
2.1M
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
505 Penobscot Drive · Palo Alto, CA 94063 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.47 | -0.85 | -80.9% | 92.26 | +4.7% | +3.7% | — | — | — | — | — |
| Feb 19, 2026 | AMC | -0.77 | -0.90 | -17.4% | 106.38 | +1.5% | -3.1% | -8.4% | +1.0% | -0.1% | +2.8% | — |
| Oct 29, 2025 | AMC | -0.48 | -0.39 | +18.8% | 72.27 | +24.5% | +27.9% | +0.7% | +6.3% | -0.8% | -3.1% | — |
| Jul 30, 2025 | AMC | -0.52 | -0.44 | +15.4% | 45.19 | -0.7% | -9.3% | +1.1% | +6.7% | +4.5% | -3.4% | — |
| Apr 30, 2025 | AMC | -0.61 | -0.49 | +19.7% | 47.23 | +11.5% | +3.5% | -4.1% | -6.0% | -4.8% | -5.2% | — |
| Feb 20, 2025 | AMC | -0.75 | -0.62 | +17.3% | 47.40 | +2.3% | -9.6% | -1.0% | -4.9% | +7.0% | -2.5% | — |
| Nov 6, 2024 | AMC | -0.55 | -0.45 | +18.2% | 25.29 | +28.1% | +13.0% | +0.1% | +2.6% | +1.3% | +6.3% | — |
| Aug 7, 2024 | AMC | -0.57 | -0.48 | +15.8% | 33.96 | -5.6% | -10.9% | -4.2% | +5.1% | -2.4% | -2.3% | — |
| May 9, 2024 | AMC | -0.72 | -0.46 | +36.1% | 19.44 | +10.2% | +15.1% | +7.3% | +3.0% | +4.1% | +1.9% | — |
| Feb 22, 2024 | AMC | -0.93 | -1.58 | -69.9% | 22.27 | -5.7% | -12.8% | +3.7% | -3.0% | -4.1% | +1.4% | — |
| Nov 6, 2023 | AMC | -0.93 | -0.73 | +21.5% | 27.74 | -2.3% | -5.4% | -9.8% | -5.0% | -4.0% | +4.9% | — |
| Aug 3, 2023 | AMC | -1.25 | -0.67 | +46.4% | 35.54 | +2.9% | +6.4% | -0.8% | -1.8% | -1.0% | -1.0% | — |
| May 9, 2023 | AMC | -1.26 | -1.30 | -3.2% | 23.99 | +8.3% | +14.9% | -1.7% | -2.7% | +5.8% | -2.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 14 | Barclays | Maintains | Overweight → Overweight | — | $82.21 | $83.04 | +1.0% | +5.1% | -1.8% | +1.0% | +5.4% | +0.8% |
| Apr 6 | Evercore ISI | Maintains | In Line → In Line | — | $93.83 | $92.68 | -1.2% | -4.4% | +4.1% | -0.5% | -6.1% | -9.8% |
| Feb 24 | Piper Sandler | Maintains | Overweight → Overweight | — | $94.42 | $95.42 | +1.1% | +1.0% | -0.1% | +2.8% | -4.2% | -1.8% |
| Feb 20 | Wells Fargo | Maintains | Overweight → Overweight | — | $106.38 | $108.00 | +1.5% | -3.1% | -8.4% | +1.0% | -0.1% | +2.8% |
| Feb 20 | BTIG | Maintains | Buy → Buy | — | $106.38 | $108.00 | +1.5% | -3.1% | -8.4% | +1.0% | -0.1% | +2.8% |
| Feb 20 | Leerink Partners | Maintains | Outperform → Outperform | — | $106.38 | $108.00 | +1.5% | -3.1% | -8.4% | +1.0% | -0.1% | +2.8% |
| Feb 20 | Stifel | Maintains | Buy → Buy | — | $106.38 | $108.00 | +1.5% | -3.1% | -8.4% | +1.0% | -0.1% | +2.8% |
| Feb 20 | Canaccord Genuity | Maintains | Buy → Buy | — | $106.38 | $108.00 | +1.5% | -3.1% | -8.4% | +1.0% | -0.1% | +2.8% |
| Feb 20 | TD Cowen | Maintains | Buy → Buy | — | $106.38 | $108.00 | +1.5% | -3.1% | -8.4% | +1.0% | -0.1% | +2.8% |
| Feb 20 | Evercore ISI | Maintains | In Line → In Line | — | $106.38 | $108.00 | +1.5% | -3.1% | -8.4% | +1.0% | -0.1% | +2.8% |
| Feb 20 | JP Morgan | Maintains | Overweight → Overweight | — | $106.38 | $108.00 | +1.5% | -3.1% | -8.4% | +1.0% | -0.1% | +2.8% |
| Feb 20 | Citigroup | Maintains | Buy → Buy | — | $106.38 | $108.00 | +1.5% | -3.1% | -8.4% | +1.0% | -0.1% | +2.8% |
| Jan 26 | Guggenheim | Maintains | Buy → Buy | — | $114.75 | $114.15 | -0.5% | -0.0% | -0.1% | -4.2% | +0.7% | +3.2% |
| Jan 9 | Stifel | Maintains | Buy → Buy | — | $108.74 | $108.17 | -0.5% | +1.3% | -2.4% | -0.6% | +1.6% | +3.1% |
| Jan 5 | Guggenheim | Maintains | Buy → Buy | — | $101.74 | $101.10 | -0.6% | +0.1% | +10.3% | -2.1% | -1.1% | +1.3% |
| Jan 5 | Evercore ISI | Downgrade | Outperform → In Line | — | $101.74 | $101.10 | -0.6% | +0.1% | +10.3% | -2.1% | -1.1% | +1.3% |
| Dec 22 | Canaccord Genuity | Maintains | Buy → Buy | — | $99.74 | $100.93 | +1.2% | +1.6% | +1.1% | -0.1% | +0.6% | -1.5% |
| Dec 17 | Mizuho | Maintains | Outperform → Outperform | — | $100.00 | $101.46 | +1.5% | -2.5% | -0.4% | +2.7% | +1.6% | +1.1% |
| Dec 15 | Wells Fargo | Maintains | Overweight → Overweight | — | $102.07 | $104.12 | +2.0% | +0.6% | -2.6% | -2.5% | -0.4% | +2.7% |
| Dec 15 | JP Morgan | Maintains | Overweight → Overweight | — | $102.07 | $104.12 | +2.0% | +0.6% | -2.6% | -2.5% | -0.4% | +2.7% |
| Dec 15 | Leerink Partners | Maintains | Outperform → Outperform | — | $102.07 | $104.12 | +2.0% | +0.6% | -2.6% | -2.5% | -0.4% | +2.7% |
| Dec 15 | Barclays | Maintains | Overweight → Overweight | — | $102.07 | $104.12 | +2.0% | +0.6% | -2.6% | -2.5% | -0.4% | +2.7% |
| Dec 12 | BTIG | Maintains | Buy → Buy | — | $101.38 | $103.52 | +2.1% | +0.7% | +0.6% | -2.6% | -2.5% | -0.4% |
| Dec 11 | Citigroup | Maintains | Buy → Buy | — | $102.62 | $104.36 | +1.7% | -1.2% | +0.7% | +0.6% | -2.6% | -2.5% |
| Dec 2 | Morgan Stanley | Maintains | Overweight → Overweight | — | $105.22 | $106.62 | +1.3% | -1.3% | +2.0% | +2.4% | -6.0% | +2.1% |
| Oct 30 | UBS | Maintains | Buy → Buy | — | $72.27 | $89.99 | +24.5% | +27.9% | +0.7% | +6.3% | -0.8% | -3.1% |
| Oct 30 | BTIG | Maintains | Buy → Buy | — | $72.27 | $89.99 | +24.5% | +27.9% | +0.7% | +6.3% | -0.8% | -3.1% |
| Oct 30 | Citigroup | Maintains | Buy → Buy | — | $72.27 | $89.99 | +24.5% | +27.9% | +0.7% | +6.3% | -0.8% | -3.1% |
| Oct 30 | Canaccord Genuity | Maintains | Buy → Buy | — | $72.27 | $89.99 | +24.5% | +27.9% | +0.7% | +6.3% | -0.8% | -3.1% |
| Oct 30 | Barclays | Maintains | Overweight → Overweight | — | $72.27 | $89.99 | +24.5% | +27.9% | +0.7% | +6.3% | -0.8% | -3.1% |
| Oct 30 | Evercore ISI | Maintains | Outperform → Outperform | — | $72.27 | $89.99 | +24.5% | +27.9% | +0.7% | +6.3% | -0.8% | -3.1% |
| Oct 22 | Piper Sandler | Maintains | Overweight → Overweight | — | $67.51 | $69.23 | +2.5% | +0.8% | +1.9% | +4.0% | -1.8% | -1.8% |
| Oct 7 | Evercore ISI | Maintains | Outperform → Outperform | — | $63.38 | $63.27 | -0.2% | +0.1% | +3.0% | -0.1% | -1.6% | -3.9% |
| Oct 2 | Barclays | Maintains | Overweight → Overweight | — | $62.65 | $62.60 | -0.1% | -1.9% | +2.2% | +0.9% | +0.1% | +3.0% |
| Sep 26 | Canaccord Genuity | Maintains | Buy → Buy | — | $60.18 | $60.18 | +0.0% | -0.2% | +3.3% | +0.8% | +0.3% | -1.9% |
| Sep 25 | Wolfe Research | Upgrade | Peer Perform → Outperform | — | $57.67 | $59.37 | +2.9% | +4.4% | -0.2% | +3.3% | +0.8% | +0.3% |
| Sep 25 | Stifel | Maintains | Buy → Buy | — | $57.67 | $59.37 | +2.9% | +4.4% | -0.2% | +3.3% | +0.8% | +0.3% |
| Sep 25 | UBS | Maintains | Buy → Buy | — | $57.67 | $59.37 | +2.9% | +4.4% | -0.2% | +3.3% | +0.8% | +0.3% |
| Sep 25 | TD Cowen | Maintains | Buy → Buy | — | $57.67 | $59.37 | +2.9% | +4.4% | -0.2% | +3.3% | +0.8% | +0.3% |
| Sep 25 | Leerink Partners | Maintains | Outperform → Outperform | — | $57.67 | $59.37 | +2.9% | +4.4% | -0.2% | +3.3% | +0.8% | +0.3% |
| Sep 25 | JP Morgan | Maintains | Overweight → Overweight | — | $57.67 | $59.37 | +2.9% | +4.4% | -0.2% | +3.3% | +0.8% | +0.3% |
| Sep 25 | BTIG | Maintains | Buy → Buy | — | $57.67 | $59.37 | +2.9% | +4.4% | -0.2% | +3.3% | +0.8% | +0.3% |
| Sep 25 | Mizuho | Maintains | Outperform → Outperform | — | $57.67 | $59.37 | +2.9% | +4.4% | -0.2% | +3.3% | +0.8% | +0.3% |
| Sep 25 | Guggenheim | Maintains | Buy → Buy | — | $57.67 | $59.37 | +2.9% | +4.4% | -0.2% | +3.3% | +0.8% | +0.3% |
| Sep 22 | BTIG | Maintains | Buy → Buy | — | $59.15 | $59.80 | +1.1% | +1.1% | -0.1% | -3.4% | +4.4% | -0.2% |
| Sep 4 | BTIG | Maintains | Buy → Buy | — | $65.06 | $60.00 | -7.8% | -5.7% | -2.0% | +0.1% | -1.2% | -4.8% |
| Jul 31 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $45.19 | $44.86 | -0.7% | -9.3% | +1.1% | +6.7% | +4.5% | -3.4% |
| Jul 31 | Raymond James | Maintains | Outperform → Outperform | — | $45.19 | $44.86 | -0.7% | -9.3% | +1.1% | +6.7% | +4.5% | -3.4% |
| Jun 13 | Mizuho | Maintains | Outperform → Outperform | — | $49.02 | $47.22 | -3.7% | +0.6% | +0.0% | +0.5% | +2.1% | -2.8% |
| May 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $44.05 | $43.30 | -1.7% | -4.8% | -5.2% | +4.9% | +0.1% | -0.1% |
No insider trades available.
8-K
Guardant Health, Inc. -- 8-K Filing
Guardant Health filed an 8-K with the SEC, likely containing material events or updates affecting the oncology diagnostics company that investors should monitor for potential impacts on stock performance.
Apr 27
8-K
Guardant Health, Inc. -- 8-K Filing
Guardant Health delivered 39% revenue growth in Q4 2025 across oncology and screening, guiding 2026 revenue growth of 27-30%, signaling sustained expansion but moderating growth rate.
Feb 19
Data updated apr 25, 2026 11:20am
· Source: massive.com